Purpose: To report the use of a coronary bioresorbable vascular scaffold to treat subclavian artery disease. Case Report: A 58-year-old man was admitted for left subclavian steal syndrome. Angiography showed significant left subclavian stenosis in proximity to the ostium of the left vertebral artery. To maximize radial support and minimize restenosis risk while avoiding the chance of vertebral compromise, a coronary bioresorbable vascular scaffold (3.5×28 mm) was implanted after predilation. The device was postdilated with a 1.0-mm oversized balloon, with immediate improvement in hemodynamics and symptoms. Two-year clinical and imaging follow-up confirmed vessel patency. Conclusion: This clinical vignette highlights the flexibility and potential of bioresorbable devices for endovascular specialists and calls for further development and use of this innovative technology.
OchoaVMYeghiazariansY.Subclavian artery stenosis: a review for the vascular medicine practitioner. Vasc Med. 2011;16:29–34.
2.
SongLZhangJLiJ. Endovascular stenting vs. extrathoracic surgical bypass for symptomatic subclavian steal syndrome. J Endovasc Ther. 2012;19:44–51.
3.
TangFWangQHuC. Use of the Szabo technique to guide accurate stent placement at the vertebral artery ostium. J Endovasc Ther. 2013;20:554–560.
4.
SogaYTomoiYFujiharaM; SCALLOP Investigators. Perioperative and long-term outcomes of endovascular treatment for subclavian artery disease from a large multicenter registry. J Endovasc Ther. 2015;22:626–633.
5.
WiebeJNefHMHammCW.Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541–2551.
6.
GonzaloNMacayaC.Absorbable stent: focus on clinical applications and benefits. Vasc Health Risk Manag. 2012;8:125–132.
7.
CaiazzoGKilicIDFabrisE. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience?Int J Cardiol. 2015;201:129–136.
8.
EllisSGKereiakesDJMetzgerDC; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–1915.
WernerMMicariACioppaA. Evaluation of the biodegradable peripheral Igaki-Tamai Stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study. JACC Cardiovasc Interv. 2014;7:305–312.
11.
OrmistonJAWebberBUbodB. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015;11:60–67.
